RegisterLogin

Ompenaclid

CAT: 0804-HY-W015828-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-W015828-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy[1][2].
CAS Number
[353-09-3]
Product Name Alternative
RGX-202; 3-Guanidinopropionic acid
UNSPSC
12352211
Hazard Statement
H315, H319, H335
Target
Apoptosis; Endogenous Metabolite
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ompenaclid.html
Concentration
10mM
Purity
99.94
Solubility
DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : ≥ 50 mg/mL
Smiles
O=C(O)CCNC(N)=N
Molecular Formula
C4H9N3O2
Molecular Weight
131.14
Precautions
H315, H319, H335
References & Citations
[1]Kurth I, et al. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 Oct 8;7 (41) :eabi7511.|[2]Creisméas A, et, al. TRPC1 and TRPC3 involvement in DMD physiopathology and as potential targets for treatment in complement to rAAV-microdystrophin. 2021 Oct 1;13.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Human Endogenous Metabolite

Related Products

CatalogName

Alternative Products

CatalogName

Popular Products